| Company Name | Website | Info | Country |
|---|---|---|---|
| Abilita Bio | http://www.abilitabio.com/ | Membrane protein drug discovery. Development of Nav1.7 and Nav1.8 modulators for pain management. | USA |
| Ablynx | https://www.ablynx.com/ | Development of nanobodies. Their website states that multiple programmes are on-going, both internally and with partners. | Belgium |
| Acesion Pharma | http://www.acesionpharma.com | Development of SK channel inhibitors for the treatment of atrial fibrillation. | Denmark |
| Algiax Pharmaceuticals | http://www.algiax.com/ | Development of GABA-A modulators for the treatment of neuropathic pain and diabetes. | Germany |
| Alion Pharmaceuticals | https://www.alion-pharmaceuticals.com | Develops small molecules targeting ion channels to treat CNS diseases. | USA |
| Amgen | https://www.amgen.com/ | Development of Nav1.7 modulators for pain management. | USA |
| Asana BioSciences | https://www.asanabiosciences.com/ | Develoment of ASN008, a topical sodium channel blocker, for the treatment of pruritus, atopic dermatitis and pain. ASN009, a P2X3 antagonist, for the treatment of cough, pruritus and pain. | USA |
| Autifony Therapeutics | https://autifony.com | Modulators of Kv3.1 and Kv3.2 channels to treat disorders of the central nervous system. | United Kingdom |
| BELLUS Health | https://bellushealth.com/ | Development of BLU-5937, a highly selective P2X3 antagonist, for the treatment of chronic cough and chronic pruritus. | Canada |
| Biogen | https://www.biogen.com | Development of Nav1.7 blockers for the treatment of neuropathic pain (BIIB074 -vixotrigine and BIIB095). | USA |
| Bionomics | https://www.bionomics.com.au | BNC210 - negative modulator of an alpha7 nicotinic acetylcholine receptor for the treatment of anxiety disorders. | Australia |
| Biosceptre | http://www.biosceptre.com/ | Development of cancer therapeutics targeting nfP2X7. | United Kingdom |
| Cadent Therapeutics | http://www.cadenttx.com | Modulators of SK channels and NMDA receptors to treat movement and cognitive disorders. | USA |
| Calchan | http://www.calchan.co.uk | CNV2197944 small molecule blocker of Cav2.2 for management of chronic pain. | United Kingdom |
| CalciMedica | https://www.calcimedica.com/ | Development of CRAC channel inhibitors for the treatment of acute and chronic inflammatory diseases. | USA |
| Caraway Therapeutics | https://carawaytx.com/ | Development of TRPML1 modulators for the treatment of neurodegenerative disorders. | USA |
| Casma Therapeutics | https://www.casmatx.com/ | Development of TRPML1 agonist for the treatment of muscular dystrophy. | USA |
| Cavion | http://cavionpharma.com | Development of T-type calcium channel modulators for movement disorders and rare, pediatric epilepsies. | USA |
| Celex Oncology | http://celex-oncology.com | Development of voltage-gated sodium channel modulators for treating aggressive, invasive and metastatic cancer forms. | UK |
| CerSci Therapeutics | https://cersci.com/ | Development of CT-044, a powerful reactive species decomposition accelerant, preventing hyper-activation of TRPA1 to treat acute post-operative and chronic neuropathic pain. | USA |
| Cerevel Therapeutics | https://www.cerevel.com/ | Development of CVL-865, a novel α2/3/5-subtype selective GABAA receptor positive allosteric modulator, for the treatment of epilepsy. | USA |
| Channel Biologics | Generation of biologics against difficult targets such as ion channels and GPCRs for the treatment of a variety of diseases. | Australia |
|
| CODA Biotherapeutics | https://www.codabiotherapeutics.com/ | Imploys gene therapy approach to express tunable ligand-gated ion channels in neurons for the treatment of neurological diseases | USA |
| CyThera Pharmaceuticals | https://www.cytherapharm.com/ | Development of Kv1.3 inhibitor for the treatment of autoimmune diseases. | USA |
| Daewoong Pharmaceutical | https://www.daewoong.com | Development of ion channel-targeting molecules for the treatment of noise-induced hearing loss. Non-opioid analgesics targeting Nav1.7. | South Korea |
| Engrail Therapeutics | https://engrail.com/ | Development of ENX-101, a sub-type selective GABA A modulator for the treatment of diseases of the nervous system. | USA |
| Enterprise Therapeutics | http://enterprisetherapeutics.com | TMEM16A potentiator and ENaC blocker for the treatment of respiratory diseases. | United Kingdom |
| Flexion Therapeutics | https://flexiontherapeutics.com/ | Development of FX301 (funapide), a locally administered NaV1.7 inhibitor for control of post-operative pain. | USA |
| Genentech | https://www.gene.com/ | Development of TRPA1 modulators | USA |
| Glenmark Pharmaceuticals | http://www.glenmarkpharma.com | GRC 17536, a TRPA1 antagonist, to treat neuropathic pain. | India |
| Goldfinch Bio | https://www.goldfinchbio.com/ | Develompent of GFB-887, a sub-type selective, small molecule TRPC5 ion channel inhibitor for the treatment of kidney diseases. | USA |
| Idorsia Pharmaceuticals | https://www.idorsia.com | Development of ACT-709478 - T-type calcium channel blocker for the treatment of epilepsy. | Switzerland |
| Imbrium Therapeutics | http://www.imbriumthera.com | A subsidiary of Purdue Pharma. Collaboration with TetraGenetics on the discovery and development of non-opioid biologic therapies (monoclonal antibodies) for the treatment of chronic pain. Undisclosed ion channel targets. | USA |
| ImmunoPrecise | http://modiquestresearch.nl/ | In collaboration with TetraGenetics the company is developing human monoclonal antibodies against three undisclosed therapeutically-relevant ion-channels. | The Netherlands |
| iN Therapeutics | A spinoff of Daewoong Pharmaceutical. Development of non-opioid analgesics targeting Nav1.7. | South Korea |
|
| Integral Molecular | https://www.integralmolecular.com/ | Preclinical monoclonal antibody discovery programs. Development of MABs against Kv1.3 and P2X7 (immune modulation), P2X3 and Nav1.7 (pain). | USA |
| Ionis Pharmaceuticals | https://www.ionispharma.com/ | Development of RNA-targeted therapeutics. Developent of the ENaC antisense oligonucleotides for the treatment of cystic fibrosis. Co-development of PRAX-222/RC-222, SCN2A antisense oligonucleotide, together with Ionis and RogCon. | USA |
| IONTAS | https://www.iontas.co.uk/ | Development of innovative antibody technologies facilitating targeting of ion channels. KnotBody® Technology. Active programs on Kv1.3, NaV1.7 & ASIC1a. | United Kingdom |
| Kineta | https://www.kinetabio.com | alpha9alpha10 nAChR antagonists for the treatment of chronic pain. | USA |
| Knopp Biosciences | https://knoppbio.com/ | Development of Kv7 modulators for the treatmnet of epileptic encelophaty, neuropathic pain, hearing disorders and ALS | USA |
| Lilly | https://www.lilly.com | TRPA1 antagonist for pain management (preclinical TRPA1 program acquired from Hydra Biosciences in 2018). | USA |
| Merck | https://www.merck.com/ | Development of TRPML1 agonists for the treatment of neurodegenerative disorders; Gefapixant, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough. | Germany |
| Neurocrine Biosciences | https://www.neurocrine.com/ | Development of Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors, for the treatment of neurological disorders. Partnership with Xenon. | USA |
| NMD Pharma | http://www.nmdpharma.com/ | Development of ClC-1 chloride channel blockers for the treatment of neuromuscular disorders | Denmark |
| Nocion Therapeutics | https://www.nociontx.com | Development of small molecules called nocions, which are sodium channel blockers, for the treatment of serious conditions including cough, itch, pain, and inflammation. | USA |
| Novassay | http://www.novassay.com | Ion channel drug development programs in Neuropathic Pain and Oncology. CACNA2D1 subunit. | Switzerland |
| Ono Pharma | https://www.ono.co.jp/eng/ | Interested in the development of novel modulators of potassium channels | Japan |
| Pano Therapeutics | Development of mitochondrial ion channel modulators for the treatment of cancer and cardiometabolic syndromes. | USA | |
| Parion Sciences | http://www.parion.com | ENaC inhibitors for the treatment of pulmonary diseases (in partnership with Vertex) and dry eye disease. Small molecule CFTR correctors for the treatment of cystic fibrosis. | USA |
| PILA PHARMA | http://pilapharma.com/ | PILA PHARMA is developing a TRPV1 antagonist, XEN-D0501, for the treatment of diabetes. | Sweden |
| Praxis | https://praxismedicines.com/ | Development of PRAX-114, a GABAA positive allosteric modulator for the treatment of major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel blocker for the treatment of essential tremor. | USA |
| QUE Oncology | https://www.queoncology.com/ | Apparently, the development of drugs and antibodies targeting the ORAI1 channel in breast cancer. | USA-Australia |
| QurAlis | https://quralis.com/ | Development of Kv7.2/7.3 modulators for the treatment of amyotrophic lateral sclerosis. | USA |
| Redpin Therapeutics | https://www.redpinrx.com/ | Development of an ultrapotent ion channel-based chemogenetics platform that enables targeted cell activation or inhibition controlled by low doses of the anti-smoking drug varenicline (CHANTIX®). | USA |
| Regulonix | https://regulonix.com | Developing non-opioid therapeutics that relieve chronic pain. NaV1.7. | USA |
| Rhizen Pharmaceuticals | http://www.rhizen.com/ | Development of CRAC channel inhibitor RP4010 for cancer treatment. | Switzerland |
| RogCon Biosciences | https://www.rogcon.com/ | Discovery and development of novel therapeutics for children suffering from SCN2A mutations. | USA |
| RogCon U.R. | https://www.rogcon.com/ | RogCon U.R., a sister company of RogCon Biosciences, is focused on the research and development of novel, disease-modifying compounds that up-regulate SCN2A for the treatment of loss-of-function mutations in SCN2A causing autism and epilepsy. | USA |
| Salipro Biotech | https://www.salipro.com/ | Development of drugs targeting membrane proteins using its proprietary nano-membrane technology. Undisclosed ion channel target. | Sweden |
| Saniona | https://saniona.com | SAN711 (a selective GABAA alpha3 modulator) for treatment of chronic itching and neuropathic pain. CAD-1883 (a first-in-class selective positive allosteric modulator of SK channels) for the treatment of essential tremor and spinocerebellar ataxia. Development of modulators of nicotinic acetylcholine (nAChRs) receptors for therapy against Parkinson's disease. Development of IK potassium channel (KCa3.1) modulator medicine for inflammatory bowel diseases. Kv7 programs for the treatment of epilepsy, pain, and urinary incontinence. | Denmark |
| selectION | http://selectiontherapeutics.com | si-544 - Kv1.3 blocker for treatment of effector memory T cell driven diseases. | USA |
| Shionogi | https://www.shionogi.com/ | Development of a P2X3 antagonist, S-600918, for the treatment of refractory chronic cough | Japan, USA |
| SiteOne Therapeutics | https://www.siteonetherapeutics.com | Small molecule inhibitors of Nav 1.7 sodium channel to treat acute and chronic pain. | USA |
| Soricimed Biopharma | https://www.soricimed.com | SOR-C13 peptide inhibiting TRPV6 for cancer treatment. | Canada |
| Stoke Therapeutics | https://www.stoketherapeutics.com/ | Development of STK-001 anti-sense oligonucleotide medicine increasing healthy copies of the Nav1.1 (SCN1A) sodium channel for the treatment of Dravet syndrome. | USA |
| TetraGenetics | http://www.tetragenetics.com | Discovery and development of novel ion channel therapeutics for autoimmune diseases and pain using proprietary technology TetraExpress | USA |
| Teva | https://www.tevapharm.com/ | Ion channel antibody discovery programs. | Israel, USA |
| Theranyx | https://www.theranyx.com/ | Development of TherabodiesTM that act on several ion channels involved in pain and cancer. | France |
| Vast Bioscience | http://www.vastbioscience.com/ | Developing non-opioid pain therapeutics targeting Nav1.7 and Nav1.8. | Australia |
| Vertex Pharmaceuticals | https://www.vrtx.com/ | Developing medicines targeting CFTR for the treatment of cystic fibrosis. ENaC inhibitors for the treatment of pulmonary diseases (in partnership with Parion Sciences). NaV 1.8 inhibitors for the treatment of pain. | USA |
| VistaGen Therapeutics | https://www.vistagen.com/ | Developing medications for anxiety, depression and other CNS diseases. NMDAR antagonist for the treatment of various CNS disorders. | USA |
| Xenon Pharmaceuticals | https://www.xenon-pharma.com | Development of ion channel modulators for the treatment of neurological diseases. | Canada |
| YourChoice Therapeutics | https://www.yourchoicetx.com/ | Developing hormone-free contraceptives preventing CatSper activation. | USA |